Crossmark

6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study

Crossref DOI link: https://doi.org/10.1007/s00277-026-06910-8

Published Online: 2026-03-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Zhangyan

Liu, Xiaoshi

Hong, Huangming

Lin, Tongyu
Funding

Funding for this research was provided by:

the National Natural Science Foundation of China (U24A20679)

Cancer Innovative Research Program of Sun Yat-sen University Cancer Center (CIRP-SYSUCC-0022)
License Information

Text and Data Mining valid from 2026-03-14

Version of Record valid from 2026-03-14
More Information

Article History

Received: 3 September 2025

Accepted: 16 February 2026

First Online: 14 March 2026

Declarations

:

: All procedures were performed in accordance with the general ethical principles outlined in the Declaration of Helsinki. The study was carried out after approval of the Ethics Committee of the Sichuan Cancer Hospital. Written informed consent was obtained from all participants prior to their inclusion in the study.

: The authors declare no competing interests.

: The authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below